Shots:
The global vaccine market, valued at $72.8B in 2025 and projected to reach $115.8B by 2033, continues to benefit from expanding immunization coverage, growing awareness of infectious disease prevention, and innovation across RSV, pneumococcal, HPV, and mRNA vaccines. Pfizer’s Prevnar Family led the market with $6.49B in revenue, followed by Merck’s Gardasil/Gardasil 9 ($5.23B)…
Shots:
The biopharma industry is a multi-hundred-billion-dollar market, with a projected compound annual growth rate (CAGR) of 8.6%, the global biopharma market is expected to reach $1.41T by 2034. Eli Lilly and Co. ranked first with $65.17B, followed by Pfizer ($61.19B) and AbbVie ($61.16B), reflecting strong market concentration among large-cap innovators with diversified, high-value portfolios …
Shots:
Vaccines play a critical role in combating infectious diseases by stimulating antibody production and establishing immune memory. Biopharma companies around the globe continue to drive innovation in vaccine development, targeting both infectious and preventable diseases
The global vaccine market was valued at $87.75B in 2024 and is projected to reach $151.96B by 2033, reflecting…
Shots:
Driven by a noble pursuit to ensure global health security, vaccines cater to the healthcare needs of millions and billions of people. With an instrumental role in containing the COVID-19 pandemic, immunization prevents more than 5 million deaths annually from conditions like diphtheria, tetanus, pertussis, influenza, and measles
With a global market size of…

